{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-005510","form_type":"8-K","ticker":"AEMD","cik":"0000882291","company_name":"AETHLON MEDICAL INC","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.861456+00:00","generated_at":"2026-06-11T20:58:10.221897+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aethlon Medical Q1 FY2024 net loss $3.3M, cash $12.9M; Hemopurifier progress","bullets":["Net loss widened to $3.3M for quarter ended June 30, 2023 from $2.9M a year ago; operating expenses rose 17.3% to $3.4M.","Cash balance $12.9M at quarter end; raised $1.1M net proceeds via at-the-market equity facility with H.C. Wainwright.","COVID-19 ICU trial in India remains open; second site Maulana Azad Medical College received Ethics Board approval.","Entered research collaboration with 34 Lives to test Hemopurifier in machine perfusion of recovered kidneys.","Oncology feasibility trial in Australia with NAMSA for solid tumors failing anti-PD-1 therapy is ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-005510","json":"https://secwatch.observer/filing/0001683168-23-005510.json","markdown":"https://secwatch.observer/filing/0001683168-23-005510.md","text":"https://secwatch.observer/filing/0001683168-23-005510.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882291/000168316823005510/0001683168-23-005510-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882291/000168316823005510/aethlon_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T20:58:10.221897+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bf951b20ee697a6d4a27e1ce1f1fb0451d3c0f4f","claim":"AETHLON MEDICAL INC reported first quarter ended June 30, 2023 results: net income approximately $3.3 million.","evidence_excerpt":"As a result of the above factors, the company’s net loss increased to approximately $3.3 million in the three months ended June 30, 2023, from approximately $2.9 million in the three months ended June 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882291/000168316823005510/0001683168-23-005510-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended June 30, 2023"},{"label":"Net income","value":"approximately $3.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}